Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Equivalents: 2016-2025

Historic Cash & Equivalents for Anaptysbio (ANAB) over the last 9 years, with Sep 2025 value amounting to $109.8 million.

  • Anaptysbio's Cash & Equivalents fell 42.67% to $109.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.8 million, marking a year-over-year decrease of 42.67%. This contributed to the annual value of $123.1 million for FY2024, which is 242.22% up from last year.
  • As of Q3 2025, Anaptysbio's Cash & Equivalents stood at $109.8 million, which was up 147.94% from $44.3 million recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's Cash & Equivalents registered a high of $495.7 million during Q4 2021, and its lowest value of $26.3 million during Q3 2023.
  • For the 3-year period, Anaptysbio's Cash & Equivalents averaged around $80.5 million, with its median value being $71.8 million (2024).
  • As far as peak fluctuations go, Anaptysbio's Cash & Equivalents tumbled by 85.62% in 2022, and later soared by 628.58% in 2024.
  • Quarterly analysis of 5 years shows Anaptysbio's Cash & Equivalents stood at $495.7 million in 2021, then crashed by 85.62% to $71.3 million in 2022, then crashed by 49.56% to $36.0 million in 2023, then skyrocketed by 242.22% to $123.1 million in 2024, then crashed by 42.67% to $109.8 million in 2025.
  • Its Cash & Equivalents stands at $109.8 million for Q3 2025, versus $44.3 million for Q2 2025 and $98.6 million for Q1 2025.